
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Document Content</title>
    <style>
        body { font-family: Arial, sans-serif; line-height: 1.6; max-width: 900px; margin: auto; padding: 20px; }
        table { border-collapse: collapse; width: 100%; margin-top: 20px; margin-bottom: 20px; }
        th, td { border: 1px solid #cccccc; text-align: left; padding: 8px; font-size: 12px; }
        tr:nth-child(even) { background-color: #f9f9f9; }
        th { background-color: #3366CC; color: white; font-weight: bold; }
        h2 { color: #4F81BD; border-bottom: 2px solid #4F81BD; padding-bottom: 5px;}
        p { margin-block-start: 0.5em; margin-block-end: 0.5em; }
    </style>
</head>
<body>
    <p style="font-size: small; color: grey;"><i>abmd-10k 20170331.htm</i></p>
<p style="font-size: small; color: grey;"><i>Page 58 of 83</i></p>
<p style="font-size: small; color: grey;"><i>ABIOMED_10k_058.pdf</i></p>
<p>ABIOMED, INC. AND SUBSIDIARIES Consolidated Statements of Operations (in thousands, except per share data)</p>

<table>
	<tr>
		<th rowspan="2"></th>
		<th colspan="3">Fiscal Years Ended March 31,</th>
	</tr>
	<tr>
		<th>2017</th>
		<th>2016</th>
		<th>2015</th>
	</tr>
	<tr>
		<td>Revenue:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Product revenue</td>
		<td>$ 445,195</td>
		<td>$ 329,520</td>
		<td>$ 229,950</td>
	</tr>
	<tr>
		<td>Funded research and development</td>
		<td>109</td>
		<td>23</td>
		<td>361</td>
	</tr>
	<tr>
		<td></td>
		<td>445,304</td>
		<td>329,543</td>
		<td>230,311</td>
	</tr>
	<tr>
		<td>Costs and expenses:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Cost of product revenue</td>
		<td>70,627</td>
		<td>50,419</td>
		<td>39,945</td>
	</tr>
	<tr>
		<td>Research and development</td>
		<td>66,386</td>
		<td>49,759</td>
		<td>35,973</td>
	</tr>
	<tr>
		<td>Selling, general and administrative</td>
		<td>218,153</td>
		<td>164,261</td>
		<td>125,727</td>
	</tr>
	<tr>
		<td></td>
		<td>355,166</td>
		<td>264,439</td>
		<td>201,645</td>
	</tr>
	<tr>
		<td>Income from operations</td>
		<td>90,138</td>
		<td>65,104</td>
		<td>28,666</td>
	</tr>
	<tr>
		<td>Other income:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Investment income, net</td>
		<td>1,554</td>
		<td>395</td>
		<td>196</td>
	</tr>
	<tr>
		<td>Other (expense) income, net</td>
		<td>(349)</td>
		<td>339</td>
		<td>(97)</td>
	</tr>
	<tr>
		<td></td>
		<td>1,205</td>
		<td>734</td>
		<td>99</td>
	</tr>
	<tr>
		<td>Income before income taxes</td>
		<td>91,343</td>
		<td>65,838</td>
		<td>28,765</td>
	</tr>
	<tr>
		<td>Income tax provision (benefit)</td>
		<td>39,227</td>
		<td>27,691</td>
		<td>(84,923)</td>
	</tr>
	<tr>
		<td>Net income</td>
		<td>$ 52,116</td>
		<td>$ 38,147</td>
		<td>$ 113,688</td>
	</tr>
	<tr>
		<td>Basic net income per share</td>
		<td>$ 1.21</td>
		<td>$ 0.90</td>
		<td>$ 2.80</td>
	</tr>
	<tr>
		<td>Basic weighted average shares outstanding</td>
		<td>43,238</td>
		<td>42,204</td>
		<td>40,632</td>
	</tr>
	<tr>
		<td>Diluted net income per share</td>
		<td>$ 1.17</td>
		<td>$ 0.85</td>
		<td>$ 2.65</td>
	</tr>
	<tr>
		<td>Diluted weighted average shares outstanding</td>
		<td>44,658</td>
		<td>44,895</td>
		<td>42,858</td>
	</tr>
</table>
<p>The accompanying notes are an integral part of the consolidated financial statements.</p>
<p style="font-size: small; color: grey;"><i>F-4</i></p>
<p style="font-size: small; color: grey;"><i>file://usmdcvdi003.us.kworld.kpmg.com/GDC_Ops/Operations/Gayathri%20Krishnan/RPA%20Phase%20II/Kiran/HealthCare/ ... 7/23/2018</i></p>

</body>
</html>
